Cubist Pharmaceuticals is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

Product Pipeline

Ceftolozane/tazobactam

Gram-negative CXA-201

for cUTI (complicated urinary tract infection) and
cIAI (complicated intra-abdominal infection)

Pivotal Phase 3 clinical trials of antibiotic candidate ceftolozane/tazobactam, being developed to treat certain infections caused by Gram-negative bacteria, have been completed in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI)…

Dificid

News & Press

21 Apr

Cubist Announces Submission of New Drug Application for Investigational Antibiotic Ceftolozane/tazobactam

Cubist Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of its investigational antibiotic ceftolozane/tazobactam for the treatment of Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI).

Careers at Cubist

Alice

Meet Alice

Vice President of Medical Affairs, International

Alice was hired in the fall of 2013 as Vice President of Medical Affairs, International, charged with building Cubist’s Medical…

Investor Center

Cubist Pharmaceuticals Loading…
CBST (NASDAQ)